Transition Therapeutics Overview
- Year Founded
-
1987
- Status
-
Acquired/Merged
- Employees
-
18
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$58.5M
Transition Therapeutics General Information
Description
Developer of therapeutics for disease indications. The company provides a product for the treatment of Alzheimer's disease and for the treatment of diabetes.
Contact Information
Website
www.transitiontherapeutics.comCorporate Office
- 101 College Street
- Suite 220
- Toronto, Ontario M5G 1L7
- Canada
Corporate Office
- 101 College Street
- Suite 220
- Toronto, Ontario M5G 1L7
- Canada
Transition Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 31-Aug-2016 | $58.5M | Completed | Generating Revenue | ||
| 4. PIPE | 23-Jun-2014 | Completed | Generating Revenue | |||
| 3. PIPE | 02-Aug-2013 | Completed | Generating Revenue | |||
| 2. PIPE | $3.28M | Completed | Generating Revenue | |||
| 1. IPO | 28-Feb-2001 | $3.28M | $3.28M | Completed | Generating Revenue |
Transition Therapeutics Comparisons
Industry
Financing
Details
Transition Therapeutics Competitors (54)
One of Transition Therapeutics’s 54 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Transition Therapeutics Patents
Transition Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2008083280-A1 | Compounds and methods of treating insulin resistance and cardiomyopathy | Inactive | 29-Dec-2006 | ||
| US-20080139455-A1 | (2s,3s,e)-2-amino-14,14-difluoro-3-hydroxytetradec-6-enoic acid; serine palmitoyl transferase ; insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia | Inactive | 12-Oct-2006 | ||
| WO-2008046071-A2 | Compounds and methods of treating metabolic syndrome and inflammation | Inactive | 12-Oct-2006 | ||
| WO-2008043102-A2 | Vasoactive intestinal polypeptide compositions | Inactive | 06-Oct-2006 | ||
| WO-2008031032-A2 | Compounds for and methods of treating insulin resistance and inflammation | Inactive | 07-Sep-2006 | C07C229/36 |
Transition Therapeutics Signals
Transition Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oracle Investment Management | Hedge Fund | Minority |
Transition Therapeutics Acquisitions (1)
Transition Therapeutics’s most recent deal was a Merger/Acquisition with NeuroMedix for . The deal was made on 01-Jun-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NeuroMedix | 01-Jun-2007 | Merger/Acquisition | Drug Discovery |
Transition Therapeutics FAQs
-
When was Transition Therapeutics founded?
Transition Therapeutics was founded in 1987.
-
Where is Transition Therapeutics headquartered?
Transition Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Transition Therapeutics?
Transition Therapeutics has 18 total employees.
-
What industry is Transition Therapeutics in?
Transition Therapeutics’s primary industry is Drug Discovery.
-
Is Transition Therapeutics a private or public company?
Transition Therapeutics is a Private company.
-
What is the current valuation of Transition Therapeutics?
The current valuation of Transition Therapeutics is .
-
What is Transition Therapeutics’s current revenue?
The current revenue for Transition Therapeutics is .
-
How much funding has Transition Therapeutics raised over time?
Transition Therapeutics has raised $55.8M.
-
Who are Transition Therapeutics’s investors?
Oracle Investment Management has invested in Transition Therapeutics.
-
Who are Transition Therapeutics’s competitors?
Voyager Therapeutics, Vertex Pharmaceuticals, uniQure, Minerva Neurosciences, and Sangamo Therapeutics are some of the 54 competitors of Transition Therapeutics.
-
When was Transition Therapeutics acquired?
Transition Therapeutics was acquired on 31-Aug-2016.
-
Who acquired Transition Therapeutics?
Transition Therapeutics was acquired by OPKO Health.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process